Results 21 to 30 of about 1,477,269 (300)

Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori

open access: yesAntibiotics, 2020
Helicobacter pylori is a Gram-negative bacterium responsible for the development of gastric diseases. The issue of spreading antibiotic resistance of H. pylori and its limited therapeutic options is an important topic in modern gastroenterology.
Paweł Krzyżek   +2 more
doaj   +1 more source

Combinations of drugs in the Treatment of Obesity [PDF]

open access: yesPharmaceuticals, 2010
Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use.
Bruno Halpern   +6 more
openaire   +3 more sources

Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies. [PDF]

open access: yes, 2008
BACKGROUND: Most malaria-endemic countries are implementing a change in anti-malarial drug policy to artemisinin-based combination therapy (ACT). The impact of different drug choices and implementation strategies is uncertain.
Hastings, Ian M   +20 more
core   +1 more source

Looking beyond the cancer cell for effective drug combinations

open access: yesGenome Medicine, 2016
Combinations of therapies are being actively pursued to expand therapeutic options and deal with cancer’s pervasive resistance to treatment. Research efforts to discover effective combination treatments have focused on drugs targeting intracellular ...
Jonathan R. Dry   +2 more
doaj   +1 more source

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations [PDF]

open access: yes, 2014
This work was supported by grants from Breakthrough Breast Cancer and Scottish Funding Council (SRDG), and personal support to Alexey Goltsov from Scottish Informatics and Computer Science Alliance (SICSA) and to James Bown from The Northwood Trust.Drug ...
Bown, James   +22 more
core   +1 more source

Equisetin Restores Colistin Sensitivity against Multi-Drug Resistant Gram-Negative Bacteria

open access: yesAntibiotics, 2021
The overuse of antibiotics and the scarcity of new drugs have led to a serious antimicrobial resistance crisis, especially for multi-drug resistant (MDR) Gram-negative bacteria. In the present study, we investigated the antimicrobial activity of a marine
Qi Zhang   +4 more
doaj   +1 more source

DCDB: Drug combination database [PDF]

open access: yesBioinformatics, 2009
Abstract Summary: Rapid advances in pharmaceutical sciences have brought ever-increasing interests in combined therapies for better clinical efficacy and safety, especially in cases of complicated and refractory diseases. Innovative experimental technologies and theoretical frameworks are being actively developed for multicomponent drug ...
Yanbin Liu   +3 more
openaire   +2 more sources

Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. [PDF]

open access: yes, 2009
BACKGROUND: WHO estimates that only 3% of fever patients use recommended artemisinin-based combination therapies (ACTs), partly reflecting their high prices in the retail sector from where many patients seek treatment.
Catherine Goodman   +26 more
core   +1 more source

Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases? [PDF]

open access: yes, 2011
Artemisinin-based combination therapy is exerting novel selective pressure upon populations of Plasmodium falciparum across Africa. Levels of resistance to non-artemisinin partner drugs differ among parasite populations, and so the artemisinins are not ...
Mackinnon, Margaret J   +19 more
core   +1 more source

Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications

open access: yesMetabolites, 2023
Because of the high research and development cost of new drugs, the long development process of new drugs, and the high failure rate at later stages, combining past drugs has gradually become a more economical and attractive alternative.
Lei Sun   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy